Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Histone acetyltransferase 1 (HAT1) is a highly conserved enzyme responsible for the acetylation of newly synthesized histone H4 at lysine 5 and lysine 12 prior to chromatin assembly. It functions as the catalytic subunit of the type B histone acetyltransferase complex and associates with WD40 repeat-containing regulatory proteins (e.g., RbAp46/RBBP7) that enhance its activity. HAT1-mediated acetylation is crucial for chromatin replication, maturation, and is involved in transcriptional regulation by promoting nucleosome assembly and facilitating access to DNA regulatory proteins. Disruption or dysregulation of HAT1 is linked to oncogenic processes and chromatin-associated diseases, making it a relevant biological and potential therapeutic target.
Inhibition of HAT1 would decrease histone H4 acetylation, affecting chromatin assembly and gene expression, with possible anti-cancer utility in overexpressing settings. Activation would theoretically enhance acetylation and alter chromatin accessibility and transcription.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Histone acetyltransferase 1 (HAT1).